rxsight inc - RXST

RXST

Close Chg Chg %
7.82 0.57 7.29%

Closed Market

8.39

+0.57 (7.29%)

Volume: 2.12M

Last Updated:

Feb 6, 2026, 4:00 PM EDT

Company Overview: rxsight inc - RXST

RXST Key Data

Open

$7.94

Day Range

7.79 - 8.54

52 Week Range

6.33 - 34.23

Market Cap

$326.47M

Shares Outstanding

41.12M

Public Float

38.59M

Beta

1.13

Rev. Per Employee

N/A

P/E Ratio

N/A

EPS

-$0.88

Yield

0.00%

Dividend

N/A

EX-DIVIDEND DATE

SHORT INTEREST

N/A

AVERAGE VOLUME

1.27M

 

RXST Performance

1 Week
 
-3.45%
 
1 Month
 
-5.09%
 
3 Months
 
-10.46%
 
1 Year
 
-74.61%
 
5 Years
 
N/A
 

RXST Analyst Ratings

  • Sell
  • Under
  • Hold
  • Over
  • Buy
Number of Ratings 11
Full Ratings ➔

About rxsight inc - RXST

RxSight, Inc. engages in the research, development, manufacture, and sale of light adjustable lenses and related capital equipment. It also commercializes adjustable intraocular lens (IOL) that is customized after cataract surgery. The company was founded on March 5, 1997 and is headquartered in Aliso Viejo, CA.

RXST At a Glance

RxSight, Inc.
100 Columbia
Aliso Viejo, California 92656
Phone 1-949-521-7830 Revenue 139.93M
Industry Electronic Components Net Income -27,455,000.00
Sector Electronic Technology 2024 Sales Growth 57.085%
Fiscal Year-end 12 / 2025 Employees 498
View SEC Filings

RXST Valuation

P/E Current N/A
P/E Ratio (with extraordinary items) N/A
P/E Ratio (without extraordinary items) N/A
Price to Sales Ratio 9.55
Price to Book Ratio 4.942
Price to Cash Flow Ratio N/A
Enterprise Value to EBITDA -33.44
Enterprise Value to Sales 7.942
Total Debt to Enterprise Value 0.011

RXST Efficiency

Revenue/Employee 280,977.912
Income Per Employee -55,130.522
Receivables Turnover 4.656
Total Asset Turnover 0.555

RXST Liquidity

Current Ratio 11.355
Quick Ratio 10.504
Cash Ratio 9.168

RXST Profitability

Gross Margin 70.71
Operating Margin -26.341
Pretax Margin -19.585
Net Margin -19.621
Return on Assets -10.895
Return on Equity -12.434
Return on Total Capital -9.353
Return on Invested Capital -12.091

RXST Capital Structure

Total Debt to Total Equity 4.372
Total Debt to Total Capital 4.189
Total Debt to Total Assets 3.826
Long-Term Debt to Equity 4.026
Long-Term Debt to Total Capital 3.857
  • Income Statement
  • Balance Sheet
  • Cash Flow Statement

Annual Financials for Rxsight Inc - RXST

Collapse All in section
All values USD millions. 2021 2022 2023 2024 5-year trend
Sales/Revenue
22.59M 49.01M 89.08M 139.93M
Sales Growth
+53.92% +116.90% +81.77% +57.09%
Cost of Goods Sold (COGS) incl D&A
18.08M 27.68M 35.31M 40.98M
COGS excluding D&A
- - - -
-
Depreciation & Amortization Expense
3.99M 4.02M 4.24M 3.62M
Depreciation
3.99M 4.02M 4.24M 3.62M
Amortization of Intangibles
- - - -
-
COGS Growth
+39.34% +53.11% +27.59% +16.06%
Gross Income
4.52M 21.33M 53.77M 98.94M
Gross Income Growth
+164.93% +372.17% +152.09% +84.03%
Gross Profit Margin
+19.99% +43.52% +60.36% +70.71%
2021 2022 2023 2024 5-year trend
SG&A Expense
57.30M 84.65M 103.85M 135.80M
Research & Development
24.50M 25.98M 29.05M 34.37M
Other SG&A
32.80M 58.66M 74.80M 101.43M
SGA Growth
+54.42% +47.71% +22.69% +30.77%
Other Operating Expense
- - - -
-
Unusual Expense
- - (2.72M) 1.77M
-
EBIT after Unusual Expense
(50.07M) (63.32M) (51.85M) (36.86M)
Non Operating Income/Expense
5.07M 1.52M 6.57M 9.47M
Non-Operating Interest Income
- - - -
-
Equity in Earnings of Affiliates
- - - -
-
Interest Expense
3.68M 4.95M 3.31M 21.00K
Interest Expense Growth
+621.96% +34.33% -33.12% -99.37%
Gross Interest Expense
3.68M 4.95M 3.31M 21.00K
Interest Capitalized
- - - -
-
Pretax Income
(48.68M) (66.75M) (48.59M) (27.41M)
Pretax Income Growth
-276.17% -37.11% +27.21% +43.60%
Pretax Margin
-215.46% -136.20% -54.55% -19.59%
Income Tax
8.00K 9.00K 20.00K 50.00K
Income Tax - Current - Domestic
13.20M 14.92M 12.81M 19.15M
Income Tax - Current - Foreign
1.00K 1.00K (1.00K) 1.00K
Income Tax - Deferred - Domestic
(13.19M) (14.91M) (12.79M) (19.10M)
Income Tax - Deferred - Foreign
- - - -
-
Income Tax Credits
- - - -
-
Equity in Earnings of Affiliates
- - - -
-
Other After Tax Income (Expense)
- - - -
-
Consolidated Net Income
(48.69M) (66.76M) (48.61M) (27.45M)
Minority Interest Expense
- - - -
-
Net Income
(48.69M) (66.76M) (48.61M) (27.45M)
Net Income Growth
-276.57% -37.11% +27.19% +43.52%
Net Margin Growth
-215.50% -136.22% -54.57% -19.62%
Extraordinaries & Discontinued Operations
- - - -
-
Discontinued Operations
- - - -
-
Net Income After Extraordinaries
(48.69M) (66.76M) (48.61M) (27.45M)
Preferred Dividends
- - - -
-
Net Income Available to Common
(48.69M) (66.76M) (48.61M) (27.45M)
EPS (Basic)
-1.7791 -2.4133 -1.4108 -0.7064
EPS (Basic) Growth
-1,560.67% -35.65% +41.54% +49.93%
Basic Shares Outstanding
27.37M 27.66M 34.46M 38.87M
EPS (Diluted)
-1.7791 -2.4133 -1.4108 -0.7064
EPS (Diluted) Growth
-1,560.67% -35.65% +41.54% +49.93%
Diluted Shares Outstanding
27.37M 27.66M 34.46M 38.87M
EBITDA
(48.80M) (59.30M) (45.84M) (33.23M)
EBITDA Growth
-55.45% -21.51% +22.69% +27.50%
EBITDA Margin
-215.99% -121.00% -51.46% -23.75%

Snapshot

Average Recommendation HOLD Average Target Price 10.50
Number of Ratings 11 Current Quarters Estimate -0.296
FY Report Date 03 / 2026 Current Year's Estimate -1.109
Last Quarter’s Earnings -0.336 Median PE on CY Estimate N/A
Year Ago Earnings -1.066 Next Fiscal Year Estimate -1.055
Median PE on Next FY Estimate N/A

Earnings Per Share

This Quarter Next Quarter This Fiscal Next Fiscal
# of Estimates 8 8 10 9
Mean Estimate -0.30 -0.28 -1.11 -1.05
High Estimates -0.22 -0.22 -0.90 -0.76
Low Estimate -0.37 -0.33 -1.26 -1.17
Coefficient of Variance -18.34 -13.85 -9.77 -12.69

Analysts Recommendations

Current 1 Month Ago 3 Months Ago
BUY 1 1 1
OVERWEIGHT 0 0 0
HOLD 8 8 7
UNDERWEIGHT 1 1 1
SELL 1 1 1
MEAN Hold Hold Hold

Insider Actions for Rxsight Inc - RXST

Date Name Shares Transaction Value
Mar 14, 2025 Tamara R. Fountain Director 24,793 Open market or private sale of non-derivative or derivative security Non-derivative transaction at $25.71 per share 637,428.03
Feb 28, 2025 Shelley B. Thunen See remarks 125,000 Grant, award or other acq pursuant to Rule 16b-3(d) 0.00
Feb 28, 2025 Eric Weinberg See remarks 125,000 Grant, award or other acq pursuant to Rule 16b-3(d) 0.00
Feb 28, 2025 Ronald M. Kurtz President & CEO; Director 215,000 Grant, award or other acq pursuant to Rule 16b-3(d) 0.00
Feb 28, 2025 Ilya Goldshleger See remarks 125,000 Grant, award or other acq pursuant to Rule 16b-3(d) 0.00

Rxsight Inc in the News